Published in J Immunol on February 01, 2009
Deconvolution of blood microarray data identifies cellular activation patterns in systemic lupus erythematosus. PLoS One (2009) 2.98
The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus. Arthritis Rheum (2013) 2.29
Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J (2012) 1.39
Apolipoprotein A-I and its role in lymphocyte cholesterol homeostasis and autoimmunity. Arterioscler Thromb Vasc Biol (2009) 1.38
Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res (2014) 1.38
Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res (2011) 1.31
A model for personalized in vivo analysis of human immune responsiveness. Sci Transl Med (2012) 1.27
Are CD4+CD25-Foxp3+ cells in untreated new-onset lupus patients regulatory T cells? Arthritis Res Ther (2009) 1.19
Dicer insufficiency and microRNA-155 overexpression in lupus regulatory T cells: an apparent paradox in the setting of an inflammatory milieu. J Immunol (2010) 1.13
Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension. Sci Transl Med (2013) 1.05
Identity of mysterious CD4+CD25-Foxp3+ cells in SLE. Arthritis Res Ther (2010) 1.03
Dendritic cell-specific disruption of TGF-β receptor II leads to altered regulatory T cell phenotype and spontaneous multiorgan autoimmunity. J Immunol (2012) 0.99
Hypomethylation at the regulatory T cell-specific demethylated region in CD25hi T cells is decoupled from FOXP3 expression at the inflamed site in childhood arthritis. J Immunol (2014) 0.98
Immune suppression in premalignant respiratory papillomas: enriched functional CD4+Foxp3+ regulatory T cells and PD-1/PD-L1/L2 expression. Clin Cancer Res (2012) 0.98
Increased CD45RA+ FoxP3(low) regulatory T cells with impaired suppressive function in patients with systemic lupus erythematosus. PLoS One (2012) 0.95
Defective response of CD4(+) T cells to retinoic acid and TGFβ in systemic lupus erythematosus. Arthritis Res Ther (2011) 0.94
CD4+Foxp3+ regulatory T cells prolong drug-induced disease remission in (NZBxNZW) F1 lupus mice. Arthritis Res Ther (2013) 0.90
Quantification of regulatory T cells in peripheral blood of patients with systemic lupus erythematosus. Rheumatol Int (2010) 0.89
The impact of aging on regulatory T-cells. Front Immunol (2013) 0.89
The Nature of Increased Circulating CD4CD25Foxp3 T Cells in Patients with Systemic Lupus Erythematosus: A Novel Hypothesis. Open Rheumatol J (2009) 0.87
Tregs are dysfunctional in vivo in a spontaneous murine model of Crohn's disease. Mucosal Immunol (2012) 0.87
Expansion of regulatory GITR+CD25 low/-CD4+ T cells in systemic lupus erythematosus patients. Arthritis Res Ther (2014) 0.83
Autoimmune Liver Disease Post-Liver Transplantation: A Summary and Proposed Areas for Future Research. Transplantation (2016) 0.81
Compensatory T-cell regulation in unaffected relatives of SLE patients, and opposite IL-2/CD25-mediated effects suggested by coreferentiality modeling. PLoS One (2012) 0.81
T-cell specific defect in expression of the NTPDase CD39 as a biomarker for lupus. Cell Immunol (2011) 0.81
CD4⁺CD25⁻Foxp3⁺ T cells: a marker for lupus nephritis? Arthritis Res Ther (2014) 0.81
Diversification and senescence of Foxp3+ regulatory T cells during experimental autoimmune encephalomyelitis. Eur J Immunol (2013) 0.81
Altered frequency and phenotype of CD4+ forkhead box protein 3+ T cells and its association with autoantibody production in human immunodeficiency virus-infected paediatric patients. Clin Exp Immunol (2012) 0.80
[Regulatory T‑cells in systemic lupus erythematosus : IL-2 is decisive for loss of tolerance]. Z Rheumatol (2016) 0.80
Broadened T-cell repertoire diversity in ivIg-treated SLE patients is also related to the individual status of regulatory T-cells. J Clin Immunol (2012) 0.80
Imbalance of different types of CD4(+) forkhead box protein 3 (FoxP3)(+) T cells in patients with new-onset systemic lupus erythematosus. Clin Exp Immunol (2013) 0.80
Alteration of CD4CD25Foxp3 T cell level in Kawasaki disease. Korean J Pediatr (2011) 0.80
Regulatory T Cell Responses to High-Dose Methylprednisolone in Active Systemic Lupus Erythematosus. PLoS One (2015) 0.79
Dynamics of adrenal steroids are related to variations in Th1 and Treg populations during Mycobacterium tuberculosis infection in HIV positive persons. PLoS One (2012) 0.78
T regulatory cells in B-cell malignancy - tumour support or kiss of death? Immunology (2012) 0.78
Engagement of SLAMF3 enhances CD4+ T-cell sensitivity to IL-2 and favors regulatory T-cell polarization in systemic lupus erythematosus. Proc Natl Acad Sci U S A (2016) 0.77
CD4(+)CD25(-)Foxp3(+) T cells play a role in tuberculous hydrothorax rather than malignant hydrothorax. J Transl Med (2015) 0.76
Effect of Th17 and Treg axis disorder on outcomes of pulmonary arterial hypertension in connective tissue diseases. Mediators Inflamm (2014) 0.76
Altered profile of regulatory T cells and associated cytokines in mild and moderate dengue. Eur J Clin Microbiol Infect Dis (2016) 0.76
Novel Senescent Regulatory T-Cell Subset with Impaired Suppressive Function in Rheumatoid Arthritis. Front Immunol (2017) 0.76
Vitamin A improve Th17 and Treg regulation in systemic lupus erythematosus. Clin Rheumatol (2016) 0.75
Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: a longitudinal study during atorvastatin treatment. BMC Cardiovasc Disord (2016) 0.75
Immunoendocrine interactions during HIV-TB coinfection: implications for the design of new adjuvant therapies. Biomed Res Int (2015) 0.75
Oral tolerance is inducible during active dextran sulfate sodium-induced colitis. World J Gastrointest Pharmacol Ther (2016) 0.75
IL-12Rβ2 has a protective role in relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol (2015) 0.75
Protein-losing pseudomembranous colitis with cap polyposis-like features. World J Gastroenterol (2017) 0.75
Reduced Epithelial Na+/H+ Exchange Drives Gut Microbial Dysbiosis and Promotes Inflammatory Response in T Cell-Mediated Murine Colitis. PLoS One (2016) 0.75
Expansion of CD25-Negative Forkhead Box P3-Positive T Cells during HIV and Mycobacterium tuberculosis Infection. Front Immunol (2017) 0.75
Two separate effects contribute to regulatory T-cell defect in SLE patients and their unaffected relatives. Clin Exp Immunol (2017) 0.75
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum (2010) 18.82
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis (2010) 12.12
Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 7.29
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum (2004) 6.22
Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature (2006) 5.19
Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther (2005) 4.86
Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med (2002) 4.54
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis (2013) 3.25
Very recent onset arthritis--clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol (2002) 2.97
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis (2010) 2.91
Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest (2002) 2.85
Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum (2005) 2.76
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis (2014) 2.40
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis (2014) 2.24
Sonographic joint assessment in rheumatoid arthritis: associations with clinical joint assessment during a state of remission. Arthritis Rheum (2013) 2.22
Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum (2012) 2.10
Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with magnetic resonance imaging-detected synovitis and radiographic progression. Arthritis Rheumatol (2014) 2.06
EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis (2013) 2.05
The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis (2012) 2.03
Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. Ann Rheum Dis (2011) 1.97
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum (2010) 1.94
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2011) 1.93
Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov (2012) 1.91
A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford) (2009) 1.82
Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol (2005) 1.81
Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis. Ann Rheum Dis (2012) 1.81
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis (2012) 1.78
The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am (2006) 1.77
Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation (2005) 1.75
Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum (2002) 1.72
Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol (2005) 1.70
Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum (2007) 1.68
TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A (2007) 1.61
Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) and CD99 are critical in lymphatic transmigration of human dendritic cells. J Invest Dermatol (2011) 1.59
Mechanisms of Disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol (2005) 1.55
Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis (2010) 1.54
Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res Ther (2008) 1.54
Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum (2004) 1.53
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. Ann Rheum Dis (2010) 1.53
Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum (2004) 1.51
Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavior in osteoporosis. Nat Med (2009) 1.50
Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum (2009) 1.49
Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. Ann Rheum Dis (2009) 1.48
Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis (2010) 1.44
A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis (2011) 1.41
Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) (2009) 1.41
Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol (2002) 1.40
The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis (2010) 1.39
The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol (2007) 1.36
Tocilizumab. Nat Rev Drug Discov (2009) 1.36
Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. Arthritis Res Ther (2014) 1.35
Endothelial precursor cells in the synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum (2004) 1.35
The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther (2008) 1.33
Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum (2003) 1.31
Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis (2014) 1.31
The importance of reporting disease activity states in rheumatoid arthritis clinical trials. Arthritis Rheum (2008) 1.29
Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum (2011) 1.29
Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. Arthritis Rheum (2009) 1.28
Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol (2008) 1.25
Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis (2012) 1.25
Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol (2004) 1.24
Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis. J Immunol (2005) 1.24
Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. J Rheumatol (2005) 1.23
Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol (2002) 1.21
Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. Ann Rheum Dis (2013) 1.18
Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. Ann Rheum Dis (2011) 1.17
Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum (2003) 1.17
Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum (2006) 1.17
A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis (2014) 1.17
Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann N Y Acad Sci (2005) 1.15
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis (2012) 1.13
Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. Ann Rheum Dis (2007) 1.13
Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells. J Autoimmun (2010) 1.12
Reporting of long-term extension studies: lack of consistency calls for consensus. Ann Rheum Dis (2011) 1.12
Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. Arthritis Rheum (2005) 1.12
CD44 is a determinant of inflammatory bone loss. J Exp Med (2005) 1.10
Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum (2007) 1.10
Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project. Ann Rheum Dis (2013) 1.10
Lymphatic precollectors contain a novel, specialized subpopulation of podoplanin low, CCL27-expressing lymphatic endothelial cells. Am J Pathol (2008) 1.09
Arthritis induces lymphocytic bone marrow inflammation and endosteal bone formation. J Bone Miner Res (2004) 1.09
Validating the International Classification of Functioning, Disability and Health Comprehensive Core Set for Rheumatoid Arthritis from the patient perspective: a qualitative study. Arthritis Rheum (2005) 1.08
PKR-signaling in DSS-induced colitis: detrime-N-tal or prote-C-tive? Inflamm Bowel Dis (2013) 1.08
Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology (Oxford) (2010) 1.07
Criteria for early rheumatoid arthritis: from Bayes' law revisited to new thoughts on pathogenesis. Arthritis Rheum (2002) 1.07
Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis (2010) 1.06
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol (2008) 1.05
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis (2013) 1.05
Remission by composite scores in rheumatoid arthritis: are ankles and feet important? Arthritis Res Ther (2007) 1.05
Therapeutic blockade of TNF in patients with SLE-promising or crazy? Autoimmun Rev (2011) 1.04
Heme oxygenase 1 (HO-1) regulates osteoclastogenesis and bone resorption. FASEB J (2005) 1.04
The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review. Ann Rheum Dis (2011) 1.04
Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis. Arthritis Rheum (2010) 1.03